Cediranib
Recurrent Solid Neoplasm
Northwestern UniversitySmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Solid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine Northwestern University | Phase 1 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II Northwestern University | Phase 1 | CC |
Nivolumab Northwestern University | Phase 1 | CC |
Veliparib Northwestern University | Phase 1 | CC |
apn401 Wake Forest University Health Sciences | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →